TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29031455

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 101
Study: 29031861

Group type: EXPERIMENTAL
Intervention: Patient-directed nutrition (PDN)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Treatment team-directed nutrition (TTDN)
Number of subjects: 30
Study: 29032136

Group type: EXPERIMENTAL
Intervention: Vericiguat
Number of subjects: 4872

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4872
Study: 29033314

Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS) measurement of area stenosis
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: IVUS measurement of area stenosis
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: IVUS diameter measurement in nonthrombotic patients
Number of subjects: 100

Group type: COMPARATOR
Intervention: Venography measurements
Number of subjects: 100
Study: 29033369

Group type: EXPERIMENTAL
Intervention: Fecal Clostridium symbiosum
Number of subjects: 781

Group type: EXPERIMENTAL
Intervention: Combination of C. symbiosum and FIT
Number of subjects: 781

Group type: EXPERIMENTAL
Intervention: Combination of all markers (C. symbiosum, F. nucleatum, FIT, CEA)
Number of subjects: 781

Group type: COMPARATOR
Intervention: Fusobacterium nucleatum
Number of subjects: 781

Group type: COMPARATOR
Intervention: Fecal immunochemical test (FIT)
Number of subjects: 781

Group type: COMPARATOR
Intervention: Carcinoembryonic antigen (CEA)
Number of subjects: 781
Study: 29033827

Group type: EXPERIMENTAL
Intervention: Excessive sleepiness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Longer nighttime in bed
Number of subjects: 0
Study: 29033896

Group type: EXPERIMENTAL
Intervention: KDT501 treatment for 28 days
Number of subjects: 9
Study: 29034366

Group type: EXPERIMENTAL
Intervention: Sorafenib combined with chemotherapy
Number of subjects: 0
Study: 29034563

Group type: EXPERIMENTAL
Intervention: Multipoint pacing (MPP)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard biventricular pacing (BVP)
Number of subjects: 76
Study: 29035120

Group type: EXPERIMENTAL
Intervention: Electronic inhaler sensor
Number of subjects: 35
Study: 29035574

Group type: EXPERIMENTAL
Intervention: Vortioxetine (5-20 mg/day)
Number of subjects: 41
Study: 29035939

Group type: EXPERIMENTAL
Intervention: 40-mg olmesartan
Number of subjects: 4447

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4447
Study: 29036212

Group type: EXPERIMENTAL
Intervention: Dutch Healthy Nutrient and Food Score (DHNaFS)
Number of subjects: 2171

Group type: EXPERIMENTAL
Intervention: Average DHNaFS score over the preceding 41 months
Number of subjects: 2171

Group type: COMPARATOR
Intervention: Dutch Undesirable Nutrient and Food Score (DUNaFS)
Number of subjects: 2171
Study: 29036345

Group type: EXPERIMENTAL
Intervention: Cabozantinib (100 mg/day)
Number of subjects: 70
Study: 29036630

Group type: EXPERIMENTAL
Intervention: Carriers of SCNN1A rare variants
Number of subjects: 1906

Group type: COMPARATOR
Intervention: SCNN1B and SCNN1G rare variants
Number of subjects: 1906

Group type: EXPERIMENTAL
Intervention: Common variants in SCNN1A (rs11614164, rs4764586, rs3741914)
Number of subjects: 1906

Group type: EXPERIMENTAL
Intervention: Minor allele of rs4764586
Number of subjects: 1906

Group type: EXPERIMENTAL
Intervention: Minor allele of rs11614164
Number of subjects: 1906

Group type: EXPERIMENTAL
Intervention: Minor allele of rs3741914
Number of subjects: 1906
Study: 29037247

Group type: EXPERIMENTAL
Intervention: Shape Program intervention
Number of subjects: 121

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 121
Study: 29037358

Group type: EXPERIMENTAL
Intervention: Superimposed bandages (elastic and nonelastic)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Single-component bandages (elastic or nonelastic)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Superimposition of two bandages
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Superimposed bandages
Number of subjects: 25
Study: 29037448

Group type: EXPERIMENTAL
Intervention: bococizumab 0.5 mg/kg
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: bococizumab 1 mg/kg
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: bococizumab 1.5 mg/kg
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: bococizumab 3 mg/kg
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: bococizumab 6 mg/kg
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: bococizumab
Number of subjects: 189

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 189
Study: 29037481

Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 1477

Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 1477
Study: 29037983

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan at 5.4 mg/kg or greater
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Number of subjects: 24
Study: 29038072

Group type: EXPERIMENTAL
Intervention: Levonorgestrel 52 mg IUS
Number of subjects: 1714
Study: 29038094

Group type: EXPERIMENTAL
Intervention: Guided version of the transdiagnostic affect-focused psychodynamic Web-based self-help intervention for 10 weeks
Number of subjects: 82

Group type: COMPARATOR
Intervention: Unguided version of the transdiagnostic affect-focused psychodynamic Web-based self-help intervention after a waiting period of 10 weeks
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Guided version of the intervention for completers
Number of subjects: 82
Study: 29038168

Group type: EXPERIMENTAL
Intervention: Novel LDL-C estimation method
Number of subjects: 1545634

Group type: COMPARATOR
Intervention: Friedewald estimation
Number of subjects: 1545634
Study: 29038184

Group type: EXPERIMENTAL
Intervention: Participatory action research (PAR) approach to improve antibiotic prescribing quality
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PDSA (Plan-Do-Study-Act) cycles for implementing interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Process evaluation and theory building on improving antibiotic prescribing
Number of subjects: 0
Study: 29038277

Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage (BAL) procedure
Number of subjects: 0
Study: 29038338

Group type: EXPERIMENTAL
Intervention: CD19-targeted chimeric antigen receptor-modified T (CAR-T)-cell immunotherapy
Number of subjects: 133
Study: 29038340

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) plus dacarbazine (DTIC)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) plus bendamustine
Number of subjects: 22
Study: 29038891

Group type: EXPERIMENTAL
Intervention: Cyanocobalamin 1.5 µg
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Cyanocobalamin 3 µg
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Cyanocobalamin 6 µg
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Cyanocobalamin 9 µg (normal status)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Cyanocobalamin (6 µg) vs 3 µg (low status)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Cyanocobalamin (6 µg) vs 9 µg (normal status)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Cyanocobalamin vs Hydroxocobalamin
Number of subjects: 101
Study: 29040030

Group type: EXPERIMENTAL
Intervention: Nivolumab (NIVO) plus Ipilimumab (IPI)
Number of subjects: 94
Study: 29040162

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 619
Study: 29040433

Group type: EXPERIMENTAL
Intervention: Low end-tidal CO2 (etCO2)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Epinephrine administration
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: etCO2 < 2.6 kPa (20 mm Hg)
Number of subjects: 86
Study: 29040633

Group type: EXPERIMENTAL
Intervention: ARV-naive adults
Number of subjects: 987

Group type: EXPERIMENTAL
Intervention: ARV-experienced adults
Number of subjects: 987

Group type: EXPERIMENTAL
Intervention: ARV-naive children
Number of subjects: 987

Group type: EXPERIMENTAL
Intervention: ARV-naive women aged 18-24 years
Number of subjects: 987

Group type: EXPERIMENTAL
Intervention: Age in females
Number of subjects: 987
Study: 29040638

Group type: EXPERIMENTAL
Intervention: Serum progesterone < 9.2 ng/ml
Number of subjects: 244

Group type: COMPARATOR
Intervention: Serum progesterone ≥ 9.2 ng/ml
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Serum progesterone quartiles Q1-Q4
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis for serum P < 9.2 ng/ml
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Serum progesterone predictive value
Number of subjects: 244
Study: 29041923

Group type: EXPERIMENTAL
Intervention: External cephalic version (ECV)
Number of subjects: 980
Study: 29041979

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) treatment
Number of subjects: 113

Group type: COMPARATOR
Intervention: Anti-tumor necrosis factor (anti-TNF) treatment with or without MTX
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: MTX group
Number of subjects: 113

Group type: COMPARATOR
Intervention: Anti-TNF ± MTX group
Number of subjects: 113
Study: 29042362

Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOACs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study: 29042364

Group type: EXPERIMENTAL
Intervention: CD200R-CD28 fusion protein
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adoptive immunotherapy with genetically modified T cells
Number of subjects: 0
Study: 29042367

Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 302
Study: 29042391

Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy or Roux-en-Y gastric bypass
Number of subjects: 100
Study: 29042397

Group type: EXPERIMENTAL
Intervention: Low osmolality contrast (n=574)
Number of subjects: 763

Group type: COMPARATOR
Intervention: Iso-osmolality contrast (n=189)
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Low contrast volume (n=341)
Number of subjects: 763

Group type: COMPARATOR
Intervention: High contrast volume (n=422)
Number of subjects: 763
Study: 29042398

Group type: EXPERIMENTAL
Intervention: Transfemoral TAVR with PAD
Number of subjects: 19660

Group type: EXPERIMENTAL
Intervention: Nontransfemoral TAVR with PAD
Number of subjects: 19660

Group type: COMPARATOR
Intervention: Control group (without PAD)
Number of subjects: 19660
Study: 29042492

Group type: EXPERIMENTAL
Intervention: Telephone Interview of Cognitive Status (TICS)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Telephone Montreal Cognitive Assessment (T-MoCA)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Clinical Dementia Rating
Number of subjects: 105
Study: 29043014

Group type: EXPERIMENTAL
Intervention: Lanadelumab (300 mg subcutaneously) administered every 2 weeks after an initial dose on Day 0 and after the first confirmed angioedema attack for rollover patients.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lanadelumab (300 mg subcutaneously) administered every 2 weeks for non-rollover patients regardless of the first attack.
Number of subjects: 0
Study: 29043263

Group type: EXPERIMENTAL
Intervention: Rate control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rhythm control
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29043407

Group type: EXPERIMENTAL
Intervention: Thyroid surgery
Number of subjects: 33
Study: 29044787

Group type: EXPERIMENTAL
Intervention: Cryoablation using a 6-mm distal electrode catheter
Number of subjects: 397
Study: 29045037

Group type: EXPERIMENTAL
Intervention: Anti-ficolin-2 antibodies in SLE patients
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Combination of anti-ficolin-2, anti-ficolin-3, and anti-C1q
Number of subjects: 165
Study: 29045487

Group type: EXPERIMENTAL
Intervention: Active SCD-associated leg ulcers
Number of subjects: 20
Study: 29045540

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg i.v. Q3weeks until disease progression
Number of subjects: 12
Study: 29045543

Group type: EXPERIMENTAL
Intervention: Lapatinib and trastuzumab (and hormonal therapy if HR-positive) for 18 weeks
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: CelTIL score at D15
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: CelTIL at D15 as a continuous variable
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: CelTIL at D15 in LPT109096 trial
Number of subjects: 151
Study: 29045736

Group type: EXPERIMENTAL
Intervention: Anti-B-cell activating factor antibody
Number of subjects: 2262

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2262
Study: 29045739

Group type: EXPERIMENTAL
Intervention: 0.50 mg/kg bodyweight ketamine administered once i.v.
Number of subjects: 12
Study: 29046319

Group type: EXPERIMENTAL
Intervention: Intravenous Fentanyl
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no Fentanyl)
Number of subjects: 0
Study: 29046921

Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 14
Study: 29047049

Group type: EXPERIMENTAL
Intervention: Fluoroscopic Swallowing Study (FSS)
Number of subjects: 9386

Group type: COMPARATOR
Intervention: Computed Tomography (CT)
Number of subjects: 9386

Group type: COMPARATOR
Intervention: Comparison of FSS and CT
Number of subjects: 9386
Study: 29047161

Group type: EXPERIMENTAL
Intervention: Prophylactic donor lymphocyte infusion (DLI)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) GVHD prophylaxis
Number of subjects: 35
Study: 29047411

Group type: EXPERIMENTAL
Intervention: Lactate level > 1.5 mmol/L
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Mildly elevated lactate levels (1-2 mmol/L)
Number of subjects: 257
Study: 29048177

Group type: EXPERIMENTAL
Intervention: Early palliative care intervention (in-person consultation, weekly nurse coach-facilitated phone sessions, monthly follow-up)
Number of subjects: 529

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 529

Group type: COMPARATOR
Intervention: Delayed intervention (12 weeks after enrollment)
Number of subjects: 529
Study: 29049219

Group type: EXPERIMENTAL
Intervention: General anesthesia (GA)
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: Intraspinal anesthesia including epidural anesthesia (EA)
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural anesthesia (CSEA)
Number of subjects: 790

Group type: COMPARATOR
Intervention: Morbid obesity
Number of subjects: 790
Study: 29049798

Group type: EXPERIMENTAL
Intervention: Near-infrared fluorescence imaging with indocyanine green (ICG)
Number of subjects: 4
Study: 29049861

Group type: EXPERIMENTAL
Intervention: Mifepristone (200 mg) followed by Misoprostol (800 μg buccal) after 24 hours
Number of subjects: 1744

Group type: EXPERIMENTAL
Intervention: Mifepristone and Misoprostol in primary facilities
Number of subjects: 1744

Group type: EXPERIMENTAL
Intervention: Mifepristone and Misoprostol in secondary facilities
Number of subjects: 1744

Group type: EXPERIMENTAL
Intervention: Mifepristone and Misoprostol in specialty hospital
Number of subjects: 1744
Study: 29050505

Group type: EXPERIMENTAL
Intervention: Symptom checklists for ADHD
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Diagnostic procedures (parent, teacher, and self-reports)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Assessment of substance use context
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Comprehensive psychiatric assessments
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Assessment of impairment and psychiatric history
Number of subjects: 239
Study: 29050557

Group type: EXPERIMENTAL
Intervention: instantaneous wave-free ratio (iFR)
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: resting distal to aortic coronary pressure (P)
Number of subjects: 763
Study: 29050558

Group type: EXPERIMENTAL
Intervention: Resting distal to aortic coronary pressure (Pd/Pa)
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Instantaneous wave-free ratio (iFR)
Number of subjects: 435
Study: 29050636

Group type: EXPERIMENTAL
Intervention: Intervention to enhance self-regulation skills (executive functioning, emotion regulation, future-oriented thinking, approach bias) delivered via home visits.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assays of self-regulation and obesogenic eating behaviors using behavioral tasks and self-reports.
Number of subjects: 0
Study: 29051021

Group type: EXPERIMENTAL
Intervention: Nilotinib (200 mg dose identified as maximum tolerated dose)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Nilotinib (200 mg dose)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Pretreatment anti-PDGFRA antibody levels ≥ .150 optical density
Number of subjects: 33
Study: 29051134

Group type: EXPERIMENTAL
Intervention: Video-based telerehabilitation intervention (8 weekly, 1-hour sessions)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Regular routine (control group)
Number of subjects: 24
Study: 29051281

Group type: EXPERIMENTAL
Intervention: Fanconi anemia and dyskeratosis congenita
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diamond-Blackfan anemia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shwachman-Diamond syndrome
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stem cell transplantation in Fanconi anemia and dyskeratosis congenita
Number of subjects: 0

Group type: COMPARATOR
Intervention: General population
Number of subjects: 0
Study: 29051829

Group type: EXPERIMENTAL
Intervention: Cladribine tablets 3.5 mg/kg
Number of subjects: 616
Study: 29052073

Group type: EXPERIMENTAL
Intervention: Laparoscopic primary cytoreduction (LPC)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Abdominal primary cytoreduction (APC)
Number of subjects: 66
Study: 29052519

Group type: EXPERIMENTAL
Intervention: Circuit training (24-week course, starting 3 months post-TKA)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no circuit training)
Number of subjects: 34
Study: 29052782

Group type: EXPERIMENTAL
Intervention: Autologous CD4 TCR-transduced T cells
Number of subjects: 3
Study: 29053802

Group type: EXPERIMENTAL
Intervention: DHA (800 mg, algal oil) daily from 26 weeks to term
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (corn/soy oil) daily from 26 weeks to term
Number of subjects: 38
Study: 29054476

Group type: EXPERIMENTAL
Intervention: Extracellular vesicles (EVs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tumor cell-derived EVs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stromal-derived EVs
Number of subjects: 0
Study: 29054589

Group type: EXPERIMENTAL
Intervention: Omalizumab treatment
Number of subjects: 806
Study: 29054734

Group type: EXPERIMENTAL
Intervention: Computer-facilitated screening and brief advice (cSBA)
Number of subjects: 2685

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 2685
Study: 29054833

Group type: EXPERIMENTAL
Intervention: Web-based screening intervention group (n=305)
Number of subjects: 636

Group type: COMPARATOR
Intervention: Paper-based screening control group (n=331)
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Both groups (e-screening and paper-based)
Number of subjects: 636
Study: 29054923

Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC)
Number of subjects: 19
Study: 29055438

Group type: EXPERIMENTAL
Intervention: Teriflunomide for 48 weeks
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Teriflunomide for 48 weeks (switchers)
Number of subjects: 1000
Study: 29055637

Group type: COMPARATOR
Intervention: Diabetes Mellitus (DM)
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Pre-Diabetes (pre-DM)
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Normal Glucose Metabolism (NGM)
Number of subjects: 547
Study: 29055736

Group type: EXPERIMENTAL
Intervention: Low-dose CT lung cancer screening
Number of subjects: 2537
Study: 29055890

Group type: EXPERIMENTAL
Intervention: Prehospital ECG characteristics
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Initial HR <30 bpm
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Initial HR <30 bpm and QRS≥120 ms
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Location of arrest
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Atropine use
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: ALS paramedic on scene
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Successful intubation
Number of subjects: 332
Study: 29056470

Group type: EXPERIMENTAL
Intervention: Bortezomib, Cladribine, and Rituximab (VCR)
Number of subjects: 24
Study: 29056570

Group type: EXPERIMENTAL
Intervention: AZD3759 at 200 mg twice a day
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: AZD3759 at 300 mg twice a day
Number of subjects: 67
Study: 29056600

Group type: EXPERIMENTAL
Intervention: Web-based chILD management platform with a registry and biobank
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Multidisciplinary review by expert clinicians
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Subcategorisation into chILD-EU register classification
Number of subjects: 575
Study: 29057117

Group type: EXPERIMENTAL
Intervention: Triple fixed-combination bimatoprost 0.01%/brimonidine 0.15%/timolol 0.5% (TFC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dual fixed-combination brimonidine 0.2%/timolol 0.5% (DFC)
Number of subjects: 0
Study: 29057120

Group type: EXPERIMENTAL
Intervention: US-IVC guided fluid management (Group 1)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Discordant fluid management (Group 2)
Number of subjects: 33
Study: 29057273

Group type: EXPERIMENTAL
Intervention: Quantitative ultrasound (QUS)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Peripheral nerve dysfunction
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Adiposity
Number of subjects: 400
Study: 29058553

Group type: EXPERIMENTAL
Intervention: Body weight-support treadmill training (BWSTT) program
Number of subjects: 17
Study: 29058589

Group type: EXPERIMENTAL
Intervention: Experimental sepsis in ICU patients
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Experimental sepsis in rats
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Postmortem human brains from sepsis nonsurvivors
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Postmortem rat brains
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Time from sepsis onset
Number of subjects: 35
Study: 29058603

Group type: EXPERIMENTAL
Intervention: Incorporation of spirituality and religion into community-based physical activity programs
Number of subjects: 23
Study: 29058601

Group type: EXPERIMENTAL
Intervention: Standard dosing of meropenem
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: MeroRisk Calculator (tool for assessing risk)
Number of subjects: 48
Study: 29058632

Group type: EXPERIMENTAL
Intervention: Movement-oriented restorative care (MRC)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 61